Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...
MarinBio publishes validated GMP/GLP cell-based potency assay for AAV-delivered anti-CD3-anti-CD19 diabody (GP101) in Journal of Immunological Methods. This publication is a milestone for the cell & ...
Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytesâ„¢ Potency, a new class of biomarker cell ...
Quality by design is critical for cell and gene therapy manufacturing where process controls directly influence product ...
Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.
Discovery and development of biopharmaceuticals such as monoclonal antibodies requires extensive functional assessment in suitable bioassays that address safety (e.g. immunogenicity), physicochemical ...
Chimeric Antigen Receptor (CAR) T cell therapy is a pivotal treatment for hematological malignancies. However, CAR T cell products exhibit batch-to-batch variability in cell number, quality, and in ...
Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results